Celltrion
068270.KS
#824
Rank
$27.93 B
Marketcap
$124.22
Share price
0.11%
Change (1 day)
5.05%
Change (1 year)
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.

P/E ratio for Celltrion (068270.KS)

P/E ratio as of December 2025 (TTM): 116

According to Celltrion 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 116.085. At the end of 2023 the company had a P/E ratio of 59.0.

P/E ratio history for Celltrion from 2008 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202359.043.97%
202241.0-9.69%
202145.4-49.48%
202089.817.79%
201976.2-27.7%
201810545.28%
201772.6-7.14%
201678.226.52%
201561.877.15%
201434.9-3.29%
201336.1152.7%
201214.3-40.11%
201123.8-26.42%
201032.431.03%
200924.7-60.87%
200863.2785.83%
20077.13

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.